Insider Sale: Director at $PATK Sells 2,875 Shares

Director John A Forbes sold 2,875 shares of $PATK on 06-13-2025 for approximately $263,407, reducing their holdings by 5.2%. Over the last six months, $PATK insiders have conducted more purchases (7) than sales (4), while institutional investors showed increased interest with 152 adding shares in Q1 2025, notably FMR LLC and CAPITAL RESEARCH GLOBAL INVESTORS, although PRICE T ROWE ASSOCIATES INC /MD/ significantly reduced its position; analysts have issued price targets with a median of $96.0.

Analysis

A director at $PATK, John A Forbes, executed a sale of 2,875 shares on June 13, 2025, for an estimated $263,407, reducing his stake by approximately 5.2% to 52,591 shares; this transaction implies a sale price of roughly $91.62 per share. Over the preceding six months, insider trading activity at $PATK has been mixed but leaned towards accumulation, with 7 purchases compared to 4 sales. Notably, insiders Todd M. Cleveland and M. Scott Welch made substantial purchases totaling over 26,500 shares for approximately $2.28 million. In terms of institutional activity, Q1 2025 data reveals a net positive inflow, with 152 institutions adding $PATK shares versus 120 decreasing positions. Significant new or increased stakes include FMR LLC adding 1.27 million shares (+42.9%) and Capital Research Global Investors adding 1.15 million shares (+250.7%). Conversely, Price T. Rowe Associates Inc. significantly reduced its holdings by 93.9%, divesting 442,233 shares. Congressional trading involved a single sale of up to $15,000 in $PATK stock by Representative Josh Gottheimer. Analyst sentiment offers a median price target of $96.0, based on three targets issued in the last six months, ranging from $84.0 to $105.0.

Key Decisions for Investors

• Investors should weigh the recent director's sale against the broader trend of net insider buying and significant institutional accumulation, particularly by FMR LLC and Capital Research Global Investors, to assess overall insider and institutional conviction.
• Monitor for further institutional divestment following Price T. Rowe's substantial reduction, as this could signal concerns not yet widely recognized, despite overall positive institutional inflows.
• Consider the current share price in relation to the median analyst price target of $96.0 and the implied director sale price of approximately $91.62 as part of valuation analysis, noting the moderately positive sentiment signal for $PATK.